Exelixis, Inc. Files 8-K Report
Ticker: EXEL · Form: 8-K · Filed: May 20, 2024 · CIK: 939767
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: EXEL
TL;DR
EXEL filed an 8-K for 'Other Events' - details TBD.
AI Summary
On May 20, 2024, Exelixis, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." Specific details regarding the nature of these events, including any financial implications or new developments, are not elaborated upon in the provided text.
Why It Matters
This filing signifies that Exelixis, Inc. is disclosing material information to the public, which could impact investor understanding of the company's current status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' without immediate disclosed financial impact or significant operational changes.
Key Players & Entities
- EXELIXIS, INC. (company) — Registrant
- May 20, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 1851 Harbor Bay Parkway Alameda , California 94502 (address) — Principal executive offices
- 6508377000 (phone_number) — Registrant's telephone number
FAQ
What specific "Other Events" are being reported by Exelixis, Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the "Other Events" being reported, only that the filing is made under that item.
When was this 8-K report filed by Exelixis, Inc.?
The 8-K report was filed on May 20, 2024.
What is the principal executive office address for Exelixis, Inc.?
The principal executive offices are located at 1851 Harbor Bay Parkway, Alameda, California 94502.
Under which section of the Securities Exchange Act of 1934 is this 8-K filing made?
This 8-K filing is made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the Commission File Number for Exelixis, Inc.?
The Commission File Number for Exelixis, Inc. is 000-30235.
Filing Stats: 733 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2024-05-20 16:41:08
Key Financial Figures
- $0.001 — hange on which registered Common Stock $0.001 Par Value per Share EXEL The Nasdaq Sto
Filing Documents
- exel-20240520.htm (8-K) — 23KB
- exel-20240520_g1.jpg (GRAPHIC) — 54KB
- 0000939767-24-000074.txt ( ) — 275KB
- exel-20240520.xsd (EX-101.SCH) — 2KB
- exel-20240520_lab.xml (EX-101.LAB) — 21KB
- exel-20240520_pre.xml (EX-101.PRE) — 12KB
- exel-20240520_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On May 20, 2024 Exelixis, Inc. (Exelixis) announced that it has entered into a Settlement and License Agreement (the Agreement) with Cipla Ltd. and Cipla USA, Inc. (individually and collectively referred to as Cipla). This settlement resolves two patent litigations brought by Exelixis in response to Cipla's Abbreviated New Drug Application seeking approval to market generic versions of CABOMETYX (cabozantinib) tablets (20 mg / 40 mg / 60 mg) prior to the expiration of the applicable patents. Pursuant to the terms of the Agreement, Exelixis will grant Cipla a license to market generic versions of CABOMETYX in the United States beginning on January 1, 2031, if approved by the U.S. Food and Drug Administration and subject to conditions and exceptions common to agreements of this type. Additionally, in accordance with the Agreement, the parties will terminate all ongoing litigation pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (otherwise known as the Hatch-Waxman Act) between Exelixis and Cipla regarding CABOMETYX patents pending in the U.S. District Court for the District of Delaware. The Agreement is confidential and subject to review by the U.S. Federal Trade Commission (FTC) and the U.S. Department of Justice. The lawsuits will be dismissed after a period of time to allow for FTC review. This Current Report on Form 8-K contains forward-looking statements, including, without limitation, statements related to: Exelixis' obligations under the Agreement, including Exelixis' granting of a license to Cipla to market generic versions of CABOMETYX inthe United Statesbeginning onJanuary 1, 2031and termination by the parties of all ongoing Hatch-Waxman Act litigation regarding CABOMETYX patents; and the expectation that the lawsuits will be dismissed after a period of time following FTC review. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materiall
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. E XELIXIS, I NC. May 20, 2024 /s/ Jeffrey J. Hessekiel Date Jeffrey J. Hessekiel Executive Vice President, General Counsel and Secretary